Jaguar Health, Inc. (JAGX) Stock Price & Analysis
Jaguar Health, Inc. (JAGX) fell 6.48% to USD 0.96 as of July 25, 2026 at 03:44 UTC, according to Nexqual real-time market data.
JAGX last closed at USD 1.03; the session ranged USD 0.95–1.08 on volume of 161,276 shares. Market capitalization is $4.73M, with a 52-week range of USD 0.95–92.75 (NCM). Source: Nexqual, July 25, 2026 at 03:44 UTC.
Key Statistics (as of July 25, 2026 at 03:44 UTC)
| Price | USD 0.96 |
|---|---|
| Change | ▼ 6.48% (down) |
| Previous Close | USD 1.03 |
| Open | USD 1.04 |
| Day Range | USD 0.95 – 1.08 |
| 52-Week Range | USD 0.95 – 92.75 |
| Volume | 161,276 shares |
| Market Cap | $4.73M |
| Exchange | NCM |
Technical Analysis (JAGX)
Nexqual's technical model rates JAGX "SELL" based on 2 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 03:44 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 18.38 (oversold) |
| vs SMA50 | Below (USD 2.65) |
| MACD | -0.58 (negative) |
Analyst Ratings (JAGX)
Wall Street analysts rate JAGX "None", per Nexqual as of July 25, 2026 at 03:44 UTC.
| Consensus Rating | None |
|---|
Earnings (JAGX)
| Next Earnings Date | 2026-08-13 |
|---|
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2025-09-30 | USD -219.8 vs est -177.8 ▼ miss |
| 2025-06-30 | USD -259.26 vs est -249.55 ▼ miss |
| 2025-03-31 | USD -584.5 vs est -378.7 ▼ miss |
Source: Nexqual, July 25, 2026 at 03:44 UTC.
Financials & Fundamentals (JAGX)
| Total Revenue | $29.57M |
|---|---|
| Revenue Growth (YoY) | +815.60% |
| Gross Margin | +85.06% |
| Operating Margin | +50.23% |
| Profit Margin | -115.40% |
| Current Ratio | 0.65 |
| Total Cash | $7.28M |
| Total Debt | $34.31M |
| Free Cash Flow | $-2.09M |
Source: Nexqual, July 25, 2026 at 03:44 UTC.
Financial Health Score (JAGX)
Nexqual rates Jaguar Health, Inc.'s overall financial health "Weak" across five dimensions, as of July 25, 2026 at 03:44 UTC.
| Growth | Weak — Revenue -2% YoY (annual), declining |
|---|---|
| Profitability | Weak — Small revenue base — building scale |
| Balance Sheet | Mixed — $7M cash vs $34M debt |
| Cash Flow | Weak — FCF negative: -$2M, burning cash |
| Efficiency | Mixed — No data |
Ownership (JAGX)
| Insider Ownership | +0.64% |
|---|---|
| Institutional Ownership | +0.15% |
| Shares Outstanding | 4.91M |
| Float | 576,578 |
| Short % of Float | +1.52% |
Source: Nexqual, July 25, 2026 at 03:44 UTC.
Leadership (JAGX)
Jaguar Health, Inc. is led by Lisa A. Conte (age 66), Founder, CEO, President & Director, per Nexqual as of July 25, 2026 at 03:44 UTC.
| Founder, CEO, President & Director | Lisa A. Conte (age 66) |
|---|---|
| Chief Scientific Officer & Chair of Scientific Advisory Board | Pravin R. Chaturvedi (age 62) |
| Senior Director of Investor Relations, Business Development & Special Events | Peter Hodge |
| President of Jaguar International | Massimo Radaelli (age 67) |
From Jaguar Health, Inc.'s Latest SEC 10-K Filing (filed 2026-04-07)
Key Strengths & Strategy (as disclosed to the SEC)
- Jaguar Health, Inc., a commercial-stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress.
- It operates through two segments, Animal Health and Human Health.
- The company focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products.
- Its lead prescription drug is Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| OCGN | Ocugen, Inc. | USD 1.21 | ▼ 6.2% |
| BNGO | Bionano Genomics, Inc. | USD 1.11 | ▼ 0.89% |
| TNXP | Tonix Pharmaceuticals Holding C | USD 9.88 | ▼ 6.7% |
| MBAI | Check-Cap Ltd. | USD 1.1 | ▲ 8.91% |
| CTRM | Castor Maritime Inc. | USD 1.87 | ▼ 3.11% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 03:44 UTC. This page is informational and not investment advice.